Literature DB >> 1981396

Modulation of high-affinity CNS dopamine D2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide.

R K Mishra1, L K Srivastava, R L Johnson.   

Abstract

1. In our previous studies, we reported that one of the conformationally constrained analogues of PLG, 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide (PAOPA), was found to be extremely potent in enhancing the [3H]ADTN binding when membranes were preincubated with this compound. The PAOPA was without effect when directly added to assay tubes. In this study, the compound PAOPA was examined on agonist binding to high affinity state of the dopamine D2 receptor. 2. The potent analogue PAOPA was able to prevent the GTP-induced conversion of high affinity state of dopamine D2 receptor to low affinity state. 3. PLG analogue PAOPA modulates the affinity states of the dopamine D2 receptor possibly by affecting its interaction with the G-protein(s).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981396     DOI: 10.1016/0278-5846(90)90054-k

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

1.  PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia.

Authors:  Bailee Dyck; Kelly Guest; Christal Sookram; Dipannita Basu; Rodney Johnson; Ram K Mishra
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

Review 2.  Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.

Authors:  Shikha Kumari; Angelica V Carmona; Amit K Tiwari; Paul C Trippier
Journal:  J Med Chem       Date:  2020-08-04       Impact factor: 7.446

3.  Specific binding of photoaffinity-labeling peptidomimetics of Pro-Leu-Gly-NH2 to the dopamine D2L receptor: evidence for the allosteric modulation of the dopamine receptor.

Authors:  Amandeep Mann; Vaneeta Verma; Dipannita Basu; Kevin J Skoblenick; Michael G R Beyaert; Abigail Fisher; Nancy Thomas; Rodney L Johnson; Ram K Mishra
Journal:  Eur J Pharmacol       Date:  2010-05-27       Impact factor: 4.432

4.  Allosteric modulation of the dopamine receptor by conformationally constrained type VI beta-turn peptidomimetics of Pro-Leu-Gly-NH2.

Authors:  Ashish P Vartak; Kevin Skoblenick; Nancy Thomas; Ram K Mishra; Rodney L Johnson
Journal:  J Med Chem       Date:  2007-12-01       Impact factor: 7.446

5.  Development of peptidomimetic ligands of Pro-Leu-Gly-NH(2) as allosteric modulators of the dopamine D(2) receptor.

Authors:  Swapna Bhagwanth; Ram K Mishra; Rodney L Johnson
Journal:  Beilstein J Org Chem       Date:  2013-01-30       Impact factor: 2.883

6.  Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalization.

Authors:  Dipannita Basu; Yuxin Tian; Jayant Bhandari; Jian Ru Jiang; Patricia Hui; Rodney L Johnson; Ram K Mishra
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

7.  Allosteric modulation of dopamine D2L receptor in complex with Gi1 and Gi2 proteins: the effect of subtle structural and stereochemical ligand modifications.

Authors:  Justyna Żuk; Damian Bartuzi; Andrea G Silva; Monika Pitucha; Oliwia Koszła; Tomasz M Wróbel; Dariusz Matosiuk; Marián Castro; Agnieszka A Kaczor
Journal:  Pharmacol Rep       Date:  2022-01-22       Impact factor: 3.024

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.